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Most of the early studies published on soy and breast cancer were not designed to test the effect of soy; the assessment of soy intake
was usually crude and few potential confounders were considered in the analysis. In this review, we focused on studies with relatively
complete assessment of dietary soy exposure in the targeted populations and appropriate consideration for potential confounders in
the statistical analysis of study data. Meta-analysis of the 8 (1 cohort, 7 case–control) studies conducted in high-soy-consuming Asians
show a significant trend of decreasing risk with increasing soy food intake. Compared to the lowest level of soy food intake (p5mg
isoflavones per day), risk was intermediate (OR¼0.88, 95% confidence interval (CI)¼0.78–0.98) among those with modest
(B10mg isoflavones per day) intake and lowest (OR¼0.71, 95% CI¼0.60–0.85) among those with high intake (X20mg
isoflavones per day). In contrast, soy intake was unrelated to breast cancer risk in studies conducted in the 11 low-soy-consuming
Western populations whose average highest and lowest soy isoflavone intake levels were around 0.8 and 0.15mg per day,
respectively. Thus, the evidence to date, based largely on case–control studies, suggest that soy food intake in the amount consumed
in Asian populations may have protective effects against breast cancer.
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Soybeans and its products have been a staple in the Asian diet for
centuries. Soybeans are the predominant source of isoflavones, one
of the three main classes of phytoestrogens or plant oestrogens.
Genistein and daidzein are the two major isoflavones; glycitein is a
minor component. These soy isoflavone compounds are structu-
rally similar to 17-b estradiol but possess weaker oestrogenic
potencies. Given the recognised aetiologic association between
oestrogen and breast cancer risk, there is biological plausibility
that dietary soy intake may have anti-carcinogenic effect on the
breast. A favoured mechanism by which soy isoflavones may
influence breast cancer development is via their affinity and
competition with endogenous oestrogens and other substrates in
binding with oestrogen receptors (ERs). It has also been suggested
that soy isoflavones may influence breast cancer risk via their anti-
proliferative, anti-angiogenic, anti-oxidative and anti-inflamma-
tory properties (Gilani and Anderson, 2002).
Lee et al (1991) first reported a reduced risk of breast cancer
in premenopausal Singapore Chinese women who were high
consumers of soy. Since then, there has been tremendous interest
in the possible role of soy in the prevention of breast cancer.
However, there is also the concern that soy may have stimulatory
effects on the breast. Dietary genistein and highly processed soy
agents have been found to stimulate growth in the MCF-7 breast
cancer cells, and to promote breast cancer in ovaraectomised
athymic mice models (for a review, see Messina et al, 2006). In a
short term soy-feeding trial, women randomised to the soy arm
exhibited significantly higher indices of increased DNA synthesis
relative to women in the control arm, although this apparent
association failed to persist following the inclusion of 33 additional
subjects (Hargreaves et al, 1999).
The questions we would like to address in this review are as
follows: (1) What is the epidemiologic evidence on soy and breast
cancer? Is there a dose–response relationship? (2) Does the
endogenous oestrogen environment, as reflected by menopausal
status and body weight, affect this association? (3) Does timing
of soy exposure affect this association? (4) Does the type of soy
ingested affect this association, given that it can be consumed in
the form of soy products that are common in a typical Asian diet
or as fillers/extenders in processed foods?
We identified a total of 28 epidemiologic studies in English
language with sufficiently detailed information on soy and breast
cancer risk. Fourteen studies were included in the meta-analysis by
Trock et al (2006). Of the remaining 14 studies, 6 were conducted
in Asia (Hirose et al, 2005; Lee et al, 2005; Shannon et al, 2005; Ho
et al, 2006; Do et al, 2007; Nishio et al, 2007) while the rest were
conducted in various Western populations (Peterson et al, 2003;
dos Santos Silva et al, 2004; Keinan-Boker et al, 2004; Bosetti et al,
2005; Thanos et al, 2006; Touillaud et al, 2006; Fink et al, 2007;
Verheus et al, 2007). Given that Asians differ from Western
populations in terms of types and amounts of soy consumed, and
possess distinct characteristics linked to breast cancer risk, we
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RISK ASSOCIATION STUDIES IN
HIGH-SOY-CONSUMING ASIANS
In Asia, soy food is consumed traditionally as nonfermented soy
foods (tofu, sometimes known as bean curd, soybeans and soy
milk), fermented soy foods (miso and natto) or other soy products
(fried, dried and pressed soy products), and the average intake is
between 25 and 50mg of isoflavones per day (Messina et al, 2006).
In contrast, intake of soy isoflavones in Western populations is
usually less than 1.0mg of isoflavones per day and Asian soy foods
are rarely consumed. Their sources of soy isoflavones come from
some legumes, sprouts and vegetables containing small amounts of
isoflavones, and from soy flour and soy protein that are commonly
added as extenders and fillers in different bakery and canned
goods (Horn-Ross et al, 2001).
Eight of the 14 studies conducted in Asia or in Asian Americans
captured the main sources of soy intake and carefully adjusted for
relevant dietary and non-dietary potential confounders. We
excluded the remaining six (two cohort, four case–control) studies
from the meta-analysis due to incomplete assessment of soy intake
in those studies. Specifically, two studies (Wu et al, 1996; Ho et al,
2006) examined only about intake of tofu. Four other studies
(Yuan et al, 1995; Key et al, 1999; Hirose et al, 2003; Nishio et al,
2007) asked about intake of several soy foods that captured
between 40 and 60% of total soy intake in those populations.
In the eight (one cohort, seven case–control) studies with
relatively complete assessment of total soy intake, dietary soy
exposure was expressed in varying units, including grams of soy
foods per day (Lee et al, 1991, 2005; Hirose et al, 2005; Shannon
et al, 2005; Do et al, 2007), grams of soy protein per day (Lee et al,
1991; Dai et al, 2001), and milligrams of soy isoflavones per day
(Wu et al, 2002; Yamamoto et al, 2003; Hirose et al, 2005). To
facilitate comparison between individual studies, all dietary soy
exposures were converted to units of milligram of isoflavones
assuming that 1g of soy protein or 10g of soy food contain 3mg of
isoflavones (Messina et al, 2006; Trock et al, 2006).
Table 1 shows the meta-analysis of these eight studies with
information on total soy food intake and breast cancer in Asian
women. There was a statistically significant 29% reduction in the
risk of breast cancer associated with high soy intake (summary
OR¼0.71, 95% confidence interval (CI)¼0.60–0.85) compared
to the lowest level of soy intake (Table 1). Results of the
individual studies are shown in Figure 1A. Across these Asian
studies, the median cut point of the highest intake of soy
isoflavones was 20mg or more per day and the lowest intake
was 5mg or less per day. A moderate level of soy intake (median
was approximately 10mg isoflavones per day) was associated with
a statistically significant 12% reduction in risk (summary
OR¼0.88, 95% CI¼0.78–0.98) compared to the lowest level of
soy intake (Figure 1B). All but one of the studies was conducted in
Asia; exclusion of the study conducted among Asian Americans
(Wu et al, 2002) did not materially change the overall summary
risk estimate. Only one of these studies was a cohort study
(Yamamoto et al, 2003); the summary OR of the seven case–
control studies combined was similar to overall results. Test of
heterogeneity across these eight studies comparing highest vs
lowest level of soy intake showed statistically significant hetero-
geneity (P¼0.023) that was due largely to the findings of one
hospital-based case–control study, which found an increased risk
associated with high soy intake (Lee et al, 2005) (Figure 1A). The
results across the remaining seven studies were comparable; the
summary OR was 0.66 (95% CI¼0.55–0.78) (P hetero-
geneity¼0.32) comparing the highest to the lowest level of
soy intake. There was no significant heterogeneity across these
eight studies comparing moderate vs lowest level of soy intake
(P heterogeneity¼0.60) (Figure 1B).
Results were presented by menopausal status in six of these
studies; a significant inverse association was observed in both
pre-menopausal (summary OR¼0.65, 95% CI¼0.50–0.85) and
postmenopausal women (summary OR¼0.63, 95% CI¼0.46–
0.85) (Table 1). Few studies have investigated whether body size
modify the soy–breast cancer association, particularly in post-
menopausal women. Investigators in Shanghai, China, reported
that the inverse soy–breast association was more evident in
women with higher body mass index (BMI) (X25kgm
 2) than
their lower BMI counterparts (Dai et al, 2001). The authors did not
perform separate analyses in the pre- vs postmenopausal women
whose endogenous oestrogen environments were vastly different.
Premenopausal women represented about 65% of the subjects in
this Shanghai study. In our Los Angeles Asian Breast Cancer study,
we did not observe any clear modifying effects of BMI on the soy–
breast cancer association in either pre- or postmenopausal women
(unpublished data).
Two studies asked about intake of soy during adolescence. In
Shanghai, soy intake during adolescence is associated with a
greater risk reduction than adult intake (Shu et al, 2001). Similarly,
in the Los Angeles Asian Breast Cancer Study, we found that soy
intake during adolescence exhibited a stronger protective effect on
risk than adulthood exposure (Wu et al, 2002). Compared to
women who were low soy consumers during both adolescence and
adult life, women who were low soy consumers during adolescence
but were high-soy consumers during adult life displayed modestly
reduced risk without reaching statistical significance (0.88, 95%
CI¼0.61–1.18) (Wu et al, 2007a).
We also examined the results of the six excluded studies (due to
incomplete soy assessment) (Yuan et al, 1995; Wu et al, 1996; Key
Table 1 Soy intake and breast cancer risk – eight studies conducted in
Asia and in Asian Americans
Description
No. of
studies Odds ratio
95% confidence
interval
Highest (B20mg or more isoflavone per day) vs lowest (B5mg or less isoflavone per day)
All studies
a 8 0.71 (0.60–0.85)
All studies in
Asia
b
7 0.73 (0.61–0.89)
Case–control
studies
c
7 0.75 (0.62–0.89)
Premenopausal
women
d
6 0.65 (0.50–0.85)
Postmenopausal
women
d
6 0.63 (0.46–0.85)
Moderate (B10mg isoflavone per day) vs lowest (B5mg isoflavone or less per day)
All studies
e 8 0.88 (0.78–0.98)
aStudies included in meta-analysis: Lee et al (1991); Dai et al (2001); Wu et al (2002);
Yamamoto et al (2003); Hirose et al (2005); Lee et al (2005); Shannon et al (2005);
Do et al (2007). We calculated ORs associated with soy products (in g) for pre- and
postmenopausal women combined in the study by Lee et al (1991); the results in
postmenopausal women in this study were published in a 1992 paper. We also
calculated ORs for pre- and postmenopausal women combined in Hirose et al
(2005).
bExcluded Wu et al (2002) in the analysis.
cExcluded Yamamoto et al (2003)
in the analysis.
dResults were not presented by menopausal status in two studies (Dai
et al, 2001; Shannon et al 2005) and they were excluded in this analysis. Do et al
(2007) published the data in pre- and postmenopausal women separately in a
subsequent paper in 2007.
eResults were presented by tertiles (Lee et al, 1991;
Hirose et al, 2005), quartiles (Wu et al, 2002; Yamamoto et al, 2003; Lee et al, 2005;
Shannon et al, 2005; Do et al, 2007) and deciles (Dai et al, 2001) of soy intake. Risk
estimate for moderate intake was calculated using the ORs for deciles 5 and 6 in Dai
et al (2001) and the ORs for quartiles 2 and 3 in studies which presented results by
quartiles of soy intake.
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with findings of our meta analysis based on the remaining eight
studies in Asians (Table 1). A comparison of the reported ORs and
their 95% CIs in the excluded studies with the summary OR (95%
CI) showed the results of the excluded studies to be mostly
compatible with the findings of the meta-analysis.
RISK ASSOCIATION STUDIES IN LOW-SOY-
CONSUMING WESTERN POPULATIONS
In studies conducted in Western populations (including one study
of South Asians in the United Kingdom, daily soy isoflavone intake
was estimated based on intake of certain traditional Asian soy
foods and other food items for which values of isoflavones are
available and have been compiled into various databases. Average
intake of soy isoflavones was low (median was approximately
0.3mgday
 1) in these Western populations. Traditional Asian soy
foods contributed little to the total intake of soy isoflavones in
these studies: it was 3% in Norfolk-United Kingdom (Grace et al,
2004), 7% in Ultrecht, the Netherlands (Keinan-Boker et al, 2004),
24% in Germany (Linseisen et al, 2004) and 35% in the San
Lee (1991)
Lee (1991)
OR (95% Cl)
B OR (95% Cl)
0.71 (0.42, 1.21)
0.96 (0.76, 1.21)
0.83 (0.63, 1.09)
0.83 (0.59, 1.16)
0.69 (0.44, 1.09)
0.83 (0.60, 1.15)
1.13 (0.81, 1.57)
0.76 (0.52, 1.11)
0.88 (0.78, 0.98)
0.62 (0.37, 1.04)
0.66 (0.46, 0.95)
0.61 (0.39, 0.96)
0.46 (0.25, 0.84)
0.51 (0.32, 0.82)
1.6 (0.9, 2.7)
1.07 (0.68, 1.69)
0.70 (0.37, 1.19)
0.71 (0.60, 0.85)
Lee (2005)
Shannon (2005)
Do (2007)
Combined
0.25 0.5 0.75 1 1.5 2 5
0.25 0.5 0.75 1 1.5 2 5
Dai (2001)
Dai (2001)
Wu (2002)
Yamamoto (2003)
Hirose (2005)
Lee (2005)
Shannon (2005)
Do (2007)
Combined
Wu (2002)
Yamamoto (2003)
Hirose (2005)
Figure 1 (A) Highest (B20mg or more isoflavones per day) vs lowest (B5mg or less isoflavone per day) level of soy intake and breast cancer – eight
studies conducted in Asia and in Asian Americans. (B) Moderate (B10mg isoflavones per day) vs lowest (B5mg or less isoflavone per day) level of soy
intake and breast cancer – eight studies conducted in Asia and in Asian Americans. See footnote e of Table 1.
Table 2 Soy intake and breast cancer risk – 11 studies conducted in
Western populations
Description
No. of
studies Odds ratio
95% confidence
interval
Highest (B0.8mg or more isoflavone per day) vs
lowest (B0.15mg or less isoflavone per day)
All
a 11 1.04 (0.97–1.11)
Cohort/nested
case–control
b
4 1.08 (0.95–1.24)
Case–control
studies
c
7 1.02 (0.95–1.11)
aStudies included in meta-analysis: Witte et al (1997); Horn-Ross et al (2001, 2002);
Linseisen et al (2003); Peterson et al (2003); dos Santos Silva et al (2004); Grace et al
(2004); Keinan-Boker et al (2004); Bosetti et al (2005); Touillaud et al (2006); Fink
et al (2007). We estimated daily soy isoflavone intake in one study (Witte et al
(1997) by assuming that one serving of tofu per week is 50g and this is equivalent to
2.14mg isoflavone per day.
bFour cohort/nested case–control studies: Horn-Ross
et al (2002); Grace et al (2004); Keinan-Boker et al (2004); Touillard et al (2006).
cSeven case–control studies: Witte et al (1997); Horn-Ross et al (2001); Linseisan
et al (2003); Peterson et al (2003); dos Santos Silva et al (2004); Bosetti et al (2005);
Fink et al (2007).
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considerable (25–60%) proportion of soy isoflavones in these
populations was from soy components added to typical Western
foods including bakery and canned products.
Table 2 presents the meta-analysis results of these 11 studies in
Western populations, showing no association between adult soy
intake and breast cancer risk; the summary OR was 1.04 (95%
CI¼0.97–1.11) between the highest (median was 0.8mg or more
per day) vs lowest (median was 0.15mg or less per day) soy
isoflavone intake. Results of the individual studies are shown in
Figure 2. There was no significant heterogeneity among the study
results (P¼0.42). The summary ORs and corresponding 95% CIs
obtained from the four cohort/nested case–control studies and the
seven case–control studies are overlapping.
In a few of these studies conducted in Western populations
(Witte et al, 1997; Horn-Ross et al, 2001), risk patterns in relation
to Asian soy foods (i.e., tofu and others) were presented. Results
on these soy foods, at the relatively low levels consumed in the
West, are compatible with those at corresponding consumption
levels in Asian women.
To overcome the difficulties and imprecision associated with
estimating low dietary soy intake from questionnaires, baseline,
prediagnostic blood/urine isoflavone levels collected from partici-
pants of three cohorts were examined in relation to breast cancer
risk (den Tonkelaar et al, 2001; Grace et al, 2004; Verheus et al,
2007); two of these studies also had information on dietary soy
isoflavone intake (Grace et al, 2004; Keinan-Boker et al, 2004).
The combined OR (summary OR¼1.02, 95% CI¼0.84–1.23) from
these three nested case–control studies is consistent with the
finding of no association based on dietary soy isoflavones and
breast cancer risk in Western populations. There were no
differences in results by menopausal status (Horn-Ross et al,
2001; dos Santos Silva et al, 2004; Keinan-Boker et al, 2004; Bosetti
et al, 2005; Fink et al, 2007; Verheus et al, 2007). One study
examined the soy–breast cancer association by body size and
reported no differences in results (Bosetti et al, 2005).
Soy intake during adolescence and breast cancer risk was
investigated in one large Canadian case–control study (Thanos
et al, 2006). The authors reported a significant, inverse association
with a score representing intake of foods considered rich in
isoflavones. In this study population, few subjects (o5%) reported
intake of any soy foods (tofu, soybeans, soy milk and soy powder
drinks) and the most likely sources of soy isoflavones were
pancakes (mix), canned tuna and processed meats. The authors
did not perform separate analyses by type of soy consumed (as
food additives vs as soy foods). Due to the possible differential
effects of the two sources of dietary soy exposures on breast cancer
risk, it is unclear if these findings truly reflect a beneficial effect of
early life soy intake on breast cancer development.
SOY AND BREAST CANCER SURVIVAL
Few studies have investigated the effects of soy intake in women
with breast cancer. Among Chinese women in Shanghai, usual soy
food intake before breast cancer diagnosis was unrelated to
disease-free breast cancer survival after a median follow-up of 5.2
years, but information on tamoxifen use was not included
(Boyapati et al, 2005). To address the concern that soy may negate
the effect of tamoxifen (Messina et al, 2006), we investigated and
found no relationship between serum levels of tamoxifen or its
metabolites and self-reported intake of soy or serum levels of
isoflavones among a population-based sample of Asian-American
women with breast cancer (Wu et al, 2007b). Further studies are
needed to determine the effects of soy (before and after breast
cancer diagnosis), in relation to tamoxifen use and breast cancer
outcome.
SOY AND MARKERS OF BREAST CANCER RISK
It has been speculated that the protective effect of soy intake on
breast cancer could be mediated through a hormonal mechanism,
and that high soy intake may affect circulating levels of oestrogen
and sex-hormone-binding globulins and mammographic densities
in a favourable manner (Messina et al, 2006). There is suggestion
in some cross-sectional studies that circulating oestrogen and
androgen levels may be nonsignificantly decreased in association
with high-soy food intake but these effects are typically small and
the results are not consistent. Results from the nearly 20 short-
term intervention studies on soy (mainly given as supplements or
other soy protein products) and circulating oestrogen and sex-
hormone-binding globulin are mixed and this may be related to
differences in study design, small sample sizes, the amount and
source of soy isoflavones that were used, duration of supplementation
Wite (1997)
OR (95% Cl)
0.5 (0.2, 1.1)
1.00 (0.79, 1.3)
1.00 (0.7, 1.3)
0.85 (0.54, 1.33)
1.07 (0.97, 1.18)
0.61 (0.35, 1.06)
1.19 (0.98, 1.44)
0.98 (0.65, 1.48)
1.05 (0.86, 1.29)
1.00 (0.76, 1.31)
0.95 (0.74, 1.22)
1.04 (0.97, 1.11)
Keinan-Boker (2004)
Bosetti (2005)
Touillaud (2005)
Fink (2007)
Combined
0.25 0.5 0.75 1 1.5 2 5
Horn-Ross (2001)
Horn-Rose (2002)
Linseisen (2003)
Peterson (2003)
Dos Santos Silva (2004)
Grace (2004)
Figure 2 Highest (B0.8mg or more isoflavones per day) vs lowest (B0.15mg or less isoflavones per day) level of soy intake and breast cancer – 11
studies conducted in Western populations. Odds ratio (OR), 95% CI.
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et al, 2005).
Fewer studies have investigated the effect of soy intake on
mammographic density. The strongest evidence that mammo-
graphic density is significantly reduced in association with high-
soy food intake is based on a cross-sectional study we conducted
among Chinese women in Singapore. In another cross-sectional
study conducted in Hawaii, high soy intake was associated with
lower mammographic density among Chinese and Japanese
women in Hawaii but higher mammographic density in Caucasians
and Hawaiians; none of the associations was statistically sig-
nificant. Three intervention studies of 1–2 years duration,
conducted in mostly premenopausal or perimenopausal women,
failed to note any effects of soy, given as soy foods, red clover
isoflavones or isoflavone supplements, on mammographic density
(for a review, see Messina et al, 2006; Ursin et al, 2006).
Thus, the collective evidence based on circulating hormones and
mammographic density does not show any strong or consistent
oestrogenic or anti-oestrogenic effects of soy on the breast.
Differences in intestinal microflora can influence the subsequent
absorption and metabolism of soy intake. Approximately one-
third of the population is capable of producing equol, a metabolite
of daidzein. It has been suggested that differences in a woman’s
ability to produce equol may influence the extent to which her soy
consumption can impact on her risk of breast cancer development
(Setchell et al, 2002). At present, it is unclear whether failure to
take account of the differences in soy metabolism between
individuals has contributed to the inconsistencies between studies.
CONCLUSIONS
Overall data based on Asian women, mainly derived from case–
control studies, show a dose-dependent, statistically significant
association between soy food intake and breast cancer risk reduction.
There was an approximately 16% risk reduction per 10mg of
isoflavones intake per day. Age at exposure may be a co-determinant
of risk; adolescent intake shows a stronger effect on risk than intake
during adulthood. Soy intake was unrelated to breast cancer risk in
studies conducted in Western populations in which the average
intake of soy isoflavones was low (o1mg day
 1) and exposure is
mainly in the form of soy components added as fillers/extenders to
typical Western foods. There is little evidence of a modifying effect
by menopausal status or body weight on the soy–breast cancer
association. It is inconclusive whether habitual soy intake or short-
term soy supplementation influences circulating hormone levels or
mammographic density. If the beneficial effect of Asian soy foods on
breast cancer risk noted above is real, their mechanisms of action
remain to be elucidated.
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